Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis

Jesus G. Berdeja, Michael C. Heinrich, Shaker R. Dakhil, Stuart L. Goldberg, Martha Wadleigh, Philip Kuriakose, Jorge Cortes, Jerald Radich, Bret Helton, David Rizzieri, Carole Paley, Ilva Dautaj, Michael J. Mauro

Research output: Contribution to journalArticle

Abstract

ENESTnext (NCT01227577) was a single-arm, multicenter trial evaluating the rate of deep molecular response by 2 years in patients with newly diagnosed (within 6 months) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib 300 mg twice daily. Among 128 enrolled patients, 94 (73%) achieved major molecular response (MMR; BCR-ABL1 ≤ 0.1% on the International Scale [BCR-ABL1IS]) and 34 (27%) achieved confirmed MR4.5 (BCR-ABL1IS ≤0.0032% detectable or undetectable; primary endpoint) by 2 years. Three-month BCR-ABL1 levels were predictive of later responses. In exploratory analyses, digital polymerase chain reaction (PCR) detected BCR-ABL1 in 39.4% of samples from patients with confirmed MR4.5 and identified further decreases in BCR-ABL1 with continued nilotinib. Safety results, including cardiovascular events, were consistent with those in other nilotinib trials. These results further substantiate the molecular response rates associated with frontline nilotinib therapy and demonstrate the feasibility of monitoring very low BCR-ABL1 transcript levels using digital PCR.

Original languageEnglish (US)
Pages (from-to)2384-2393
Number of pages10
JournalLeukemia and Lymphoma
Volume60
Issue number10
DOIs
StatePublished - Aug 24 2019
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polymerase Chain Reaction
Leukemia, Myeloid, Chronic Phase
Multicenter Studies
Safety
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Therapeutics

Keywords

  • BCR-ABL1
  • chronic myeloid leukemia
  • deep molecular response
  • digital PCR
  • nilotinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia : a landmark analysis. / Berdeja, Jesus G.; Heinrich, Michael C.; Dakhil, Shaker R.; Goldberg, Stuart L.; Wadleigh, Martha; Kuriakose, Philip; Cortes, Jorge; Radich, Jerald; Helton, Bret; Rizzieri, David; Paley, Carole; Dautaj, Ilva; Mauro, Michael J.

In: Leukemia and Lymphoma, Vol. 60, No. 10, 24.08.2019, p. 2384-2393.

Research output: Contribution to journalArticle

Berdeja, JG, Heinrich, MC, Dakhil, SR, Goldberg, SL, Wadleigh, M, Kuriakose, P, Cortes, J, Radich, J, Helton, B, Rizzieri, D, Paley, C, Dautaj, I & Mauro, MJ 2019, 'Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis', Leukemia and Lymphoma, vol. 60, no. 10, pp. 2384-2393. https://doi.org/10.1080/10428194.2019.1590569
Berdeja, Jesus G. ; Heinrich, Michael C. ; Dakhil, Shaker R. ; Goldberg, Stuart L. ; Wadleigh, Martha ; Kuriakose, Philip ; Cortes, Jorge ; Radich, Jerald ; Helton, Bret ; Rizzieri, David ; Paley, Carole ; Dautaj, Ilva ; Mauro, Michael J. / Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia : a landmark analysis. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 10. pp. 2384-2393.
@article{3043181be2e74ced928710182de15cc5,
title = "Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis",
abstract = "ENESTnext (NCT01227577) was a single-arm, multicenter trial evaluating the rate of deep molecular response by 2 years in patients with newly diagnosed (within 6 months) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib 300 mg twice daily. Among 128 enrolled patients, 94 (73{\%}) achieved major molecular response (MMR; BCR-ABL1 ≤ 0.1{\%} on the International Scale [BCR-ABL1IS]) and 34 (27{\%}) achieved confirmed MR4.5 (BCR-ABL1IS ≤0.0032{\%} detectable or undetectable; primary endpoint) by 2 years. Three-month BCR-ABL1 levels were predictive of later responses. In exploratory analyses, digital polymerase chain reaction (PCR) detected BCR-ABL1 in 39.4{\%} of samples from patients with confirmed MR4.5 and identified further decreases in BCR-ABL1 with continued nilotinib. Safety results, including cardiovascular events, were consistent with those in other nilotinib trials. These results further substantiate the molecular response rates associated with frontline nilotinib therapy and demonstrate the feasibility of monitoring very low BCR-ABL1 transcript levels using digital PCR.",
keywords = "BCR-ABL1, chronic myeloid leukemia, deep molecular response, digital PCR, nilotinib",
author = "Berdeja, {Jesus G.} and Heinrich, {Michael C.} and Dakhil, {Shaker R.} and Goldberg, {Stuart L.} and Martha Wadleigh and Philip Kuriakose and Jorge Cortes and Jerald Radich and Bret Helton and David Rizzieri and Carole Paley and Ilva Dautaj and Mauro, {Michael J.}",
year = "2019",
month = "8",
day = "24",
doi = "10.1080/10428194.2019.1590569",
language = "English (US)",
volume = "60",
pages = "2384--2393",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia

T2 - a landmark analysis

AU - Berdeja, Jesus G.

AU - Heinrich, Michael C.

AU - Dakhil, Shaker R.

AU - Goldberg, Stuart L.

AU - Wadleigh, Martha

AU - Kuriakose, Philip

AU - Cortes, Jorge

AU - Radich, Jerald

AU - Helton, Bret

AU - Rizzieri, David

AU - Paley, Carole

AU - Dautaj, Ilva

AU - Mauro, Michael J.

PY - 2019/8/24

Y1 - 2019/8/24

N2 - ENESTnext (NCT01227577) was a single-arm, multicenter trial evaluating the rate of deep molecular response by 2 years in patients with newly diagnosed (within 6 months) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib 300 mg twice daily. Among 128 enrolled patients, 94 (73%) achieved major molecular response (MMR; BCR-ABL1 ≤ 0.1% on the International Scale [BCR-ABL1IS]) and 34 (27%) achieved confirmed MR4.5 (BCR-ABL1IS ≤0.0032% detectable or undetectable; primary endpoint) by 2 years. Three-month BCR-ABL1 levels were predictive of later responses. In exploratory analyses, digital polymerase chain reaction (PCR) detected BCR-ABL1 in 39.4% of samples from patients with confirmed MR4.5 and identified further decreases in BCR-ABL1 with continued nilotinib. Safety results, including cardiovascular events, were consistent with those in other nilotinib trials. These results further substantiate the molecular response rates associated with frontline nilotinib therapy and demonstrate the feasibility of monitoring very low BCR-ABL1 transcript levels using digital PCR.

AB - ENESTnext (NCT01227577) was a single-arm, multicenter trial evaluating the rate of deep molecular response by 2 years in patients with newly diagnosed (within 6 months) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib 300 mg twice daily. Among 128 enrolled patients, 94 (73%) achieved major molecular response (MMR; BCR-ABL1 ≤ 0.1% on the International Scale [BCR-ABL1IS]) and 34 (27%) achieved confirmed MR4.5 (BCR-ABL1IS ≤0.0032% detectable or undetectable; primary endpoint) by 2 years. Three-month BCR-ABL1 levels were predictive of later responses. In exploratory analyses, digital polymerase chain reaction (PCR) detected BCR-ABL1 in 39.4% of samples from patients with confirmed MR4.5 and identified further decreases in BCR-ABL1 with continued nilotinib. Safety results, including cardiovascular events, were consistent with those in other nilotinib trials. These results further substantiate the molecular response rates associated with frontline nilotinib therapy and demonstrate the feasibility of monitoring very low BCR-ABL1 transcript levels using digital PCR.

KW - BCR-ABL1

KW - chronic myeloid leukemia

KW - deep molecular response

KW - digital PCR

KW - nilotinib

UR - http://www.scopus.com/inward/record.url?scp=85063440030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063440030&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1590569

DO - 10.1080/10428194.2019.1590569

M3 - Article

C2 - 30912699

AN - SCOPUS:85063440030

VL - 60

SP - 2384

EP - 2393

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -